Visfatin/Nampt: An adipokine with cardiovascular impact

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Romacho, Tania ^a   Sánchez Ferrer, Carlos F ^b   Peiró, Concepción ^b  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; CHEMOKINE RECEPTOR CCR2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE A; GELATINASE B; I KAPPA B; INSULIN RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ADIPOCYTOKINE; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ANGIOGENESIS; APOPTOSIS; ARTERIAL WALL THICKNESS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL INJURY; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; INFLAMMATION; INTRAABDOMINAL FAT; KIDNEY FIBROSIS; LEUKOCYTE; LIPID STORAGE; MACROPHAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PREECLAMPSIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SUBCUTANEOUS FAT; VASCULAR SMOOTH MUSCLE; VASCULITIS; ANIMAL; ATHEROSCLEROSIS; BRAIN CIRCULATION; CHRONIC KIDNEY FAILURE; FEMALE; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PREGNANCY;

ACUTE CORONARY SYNDROME; ADIPOKINES; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CELL PROLIFERATION; CEREBROVASCULAR CIRCULATION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; MICE; NEOVASCULARIZATION, PATHOLOGIC; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; POLYCYSTIC OVARY SYNDROME; PRE-ECLAMPSIA; PREGNANCY; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84880154046     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/946427     Document Type: Review

References (126)

1. Boucher J., Masri B., Daviaud D., Gesta S., Guigné C., Mazzucotelli A., Castan-Laurell I., Tack I., Knibiehler B., Carpé né C., Audigier Y., Saulnier-Blache J., Valet P., Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005 146 4 1764 1771 2-s2.0-20144380036 10.1210/en.2004-1427 (Pubitemid 40396885)
2. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., Matsuki Y., Murakami M., Ichisaka T., Murakami H., Watanabe E., Takagi T., Akiyoshi M., Ohtsubo T., Kihara S., Yamashita S., Makishima M., Funahashi T., Yamanaka S., Hiramatsu R., Matsuzawa Y., Shimomura I., Visfatin: a protein secreted by visceral fat that Mimics the effects of insulin. Science 2005 307 5708 426 430 2-s2.0-19944433652 10.1126/science.1097243 (Pubitemid 40139988)
3. Lamers D., Famulla S., Wronkowitz N., Hartwig S., Lehr S., Ouwens D. M., Eckardt K., Kaufman J. M., Ryden M., Müller S., Hanisch F., Ruige J., Arner P., Sell H., Eckel J., Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011 60 7 1917 1925 2-s2.0-80052096595 10.2337/db10-1707
4. Steppan C. M., Bailey S. T., Bhat S., Brown E. J., Banerjee R. R., Wright C. M., Patel H. R., Ahima R. S., Lazar M. A., The hormone resistin links obesity to diabetes. Nature 2001 409 6818 307 312 2-s2.0-0035905758 10.1038/35053000 (Pubitemid 32151228)
5. Fukuhara A., Matsuda M., Nishizawa M., Retraction. Science 2007 318 5850 565
6. Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I., Cloning and characterization of the cDNA encoding a novel human pre-B- cell colony-enhancing factor. Molecular and Cellular Biology 1994 14 2 1431 1437 2-s2.0-0027958452
7. Berndt J., Klöting N., Kralisch S., Kovacs P., Fasshauer M., Schön M. R., Stumvoll M., Blüher M., Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005 54 10 2911 2916 2-s2.0-25844491778 10.2337/diabetes.54.10.2911 (Pubitemid 41401086)
8. Tan B. K., Chen J., Digby J. E., Keay S. D., Kennedy C. R., Randeva H. S., Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. Journal of Clinical Endocrinology and Metabolism 2006 91 12 5022 5028 2-s2.0-33845476276 10.1210/jc.2006-0936 (Pubitemid 44917345)
9. Cheng K. H., Chu C.S., Lee K.T., Lin T.-., Hsieh C.-., Chiu C.-., Voon W.-., Sheu S.-., Lai W.-., Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. International Journal of Obesity 2008 32 2 268 274 2-s2.0-39449083892 10.1038/sj.ijo.0803726 (Pubitemid 351271788)
10. Wang P., Xu T., Guan Y., Su D., Fan G., Miao C., Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovascular Research 2009 81 2 370 380 2-s2.0-58449109119 10.1093/cvr/cvn288
11. Curat C. A., Wegner V., Sengenès C., Miranville A., Tonus C., Busse R., Bouloumié A., Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006 49 4 744 747 2-s2.0-33644826101 10.1007/s00125-006-0173-z (Pubitemid 43357549)
12. Rongvaux A., Shea R. J., Mulks M. H., Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. European Journal of Immunology 2002 32 11 3225 3234 (Pubitemid 35414880)
13. Formentini L., Moroni F., Chiarugi A., Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochemical Pharmacology 2009 77 10 1612 1620 2-s2.0-64049094455 10.1016/j.bcp.2009.02.017
14. Revollo J. R., Grimm A. A., Imai S., The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. Journal of Biological Chemistry 2004 279 49 50754 50763 2-s2.0-10944270187 10.1074/jbc.M408388200 (Pubitemid 40017813)
15. Ho C., van der Veer E., Akawi O., Pickering J. G., SIRT1 markedly extends replicative lifespan if the NAD+ salvage pathway is enhanced. FEBS Letters 2009 583 18 3081 3085 2-s2.0-70249098847 10.1016/j.febslet.2009.08.031
16. van der Veer E., Nong Z., O'Neil C., Urquhart B., Freeman D., Pickering J. G., Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circulation Research 2005 97 1 25 34 2-s2.0-22144459034 10.1161/01.RES. 0000173298.38808.27 (Pubitemid 40982319)
17. van der Veer E., Ho C., O'Neil C., Barbosa N., Scott R., Cregan S. P., Pickering J. G., Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. Journal of Biological Chemistry 2007 282 15 10841 10845 2-s2.0-34249696938 10.1074/jbc.C700018200 (Pubitemid 47100731)
18. Revollo J. R., Korner A., Mills K. F., Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metabolism 2007 6 5 363 375 10.1016/j.cmet.2007.09.003 (Pubitemid 350011996)
19. Imai S., Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Current Pharmaceutical Design 2009 15 1 20 28 2-s2.0-62149148872 10.2174/138161209787185814
20. Pilz S., Mangge H., Obermayer-Pietsch B., März W., Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions. Journal of Endocrinological Investigation 2007 30 2 138 144 2-s2.0-34247223066 (Pubitemid 46614445)
21. Stephens J. M., Vidal-Puig A. J., An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Current Opinion in Lipidology 2006 17 2 128 131 2-s2.0-33645523472 10.1097/01.mol.0000217893.77746.4b
22. Gosset M., Berenbaum F., Salvat C., Sautet A., Pigenet A., Tahiri K., Jacques C., Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis. Arthritis and Rheumatism 2008 58 5 1399 1409 2-s2.0-43949131087 10.1002/art.23431 (Pubitemid 351705929)
23. Ognjanovic S., Ku T. L., Bryant-Greenwood G. D., Pre-B-cell colony-enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium. American Journal of Obstetrics and Gynecology 2005 193 1 273 282 2-s2.0-22244476407 10.1016/j.ajog.2004.11.003 (Pubitemid 40991856)
24. Costford S. R., Bajpeyi S., Pasarica M., Albarado D. C., Thomas S. C., Xie H., Church T. S., Jubrias S. A., Conley K. E., Smith S. R., Skeletal muscle NAMPT is induced by exercise in humans. American Journal of Physiology 2010 298 1 E117 E126 2-s2.0-73649133942 10.1152/ajpendo.00318.2009
25. Garten A., Petzold S., Barnikol-Oettler A., Körner A., Thasler W. E., Kratzsch J., Kiess W., Gebhardt R., Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochemical and Biophysical Research Communications 2010 391 1 376 381 2-s2.0-72949097428 10.1016/j.bbrc.2009.11.066
26. Frydelund-Larsen L., Akerstrom T., Nielsen S., Keller P., Keller C., Pedersen B. K., Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise. American Journal of Physiology 2007 292 1 E24 E31 2-s2.0-33846008710 10.1152/ajpendo.00113.2006 (Pubitemid 46052921)
27. Kukla M., Ciupińska-Kajor M., Kajor M., Wylezoł M., Zwirska-Korczala K., Hartleb M., Berdowska A., Mazur W., Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Polish Journal of Pathology 2010 61 3 147 153 2-s2.0-79953269789
28. Chen M. P., Chung F. M., Chang D. M., Tsai J. C.-., Huang H., Shin S., Lee Y., Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2006 91 1 295 299 2-s2.0-30344471828 10.1210/jc.2005-1475 (Pubitemid 43069152)
29. Filippatos T. D., Derdemezis C. S., Gazi I. F., Lagos K., Kiortsis D. N., Tselepis A. D., Elisaf M. S., Increased plasma visfatin levels in subjects with the metabolic syndrome. European Journal of Clinical Investigation 2008 38 1 71 72 2-s2.0-37349030756 10.1111/j.1365-2362.2007.01904.x (Pubitemid 350293863)
30. Sommer G., Garten A., Petzold S., Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clinical Science 2008 115 1 13 23 10.1042/CS20070226 (Pubitemid 351930789)
31. Vanhoutte P. M., Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circulation Journal 2009 73 4 595 601 2-s2.0-65649110801 10.1253/circj.CJ-08-1169
32. Takebayashi K., Suetsugu M., Wakabayashi S., Aso Y., Inukai T., Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007 56 4 451 458 2-s2.0-33947247655 10.1016/j.metabol.2006.12.001 (Pubitemid 46427838)
33. Uslu S., Kebapci N., Kara M., Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Experimental and Therapeutic Medicine 2012 4 1 113 120
34. Stam F., van Guldener C., Schalkwijk C. G., Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrology Dialysis Transplantation 2003 18 5 892 898 10.1093/ndt/gfg080 (Pubitemid 36592529)
35. Kadoglou N. P. E., Sailer N., Moumtzouoglou A., Kapelouzou A., Tsanikidis H., Vitta I., Karkos C., Karayannacos P. E., Gerasimidis T., Liapis C. D., Visfatin (Nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Experimental and Clinical Endocrinology and Diabetes 2010 118 2 75 80 2-s2.0-77649164023 10.1055/s-0029-1237360
36. Malavazos A. E., Ermetici F., Cereda E., Coman C., Locati M., Morricone L., Corsi M. M., Ambrosi B., Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. Nutrition, Metabolism and Cardiovascular Diseases 2008 18 8 523 530 2-s2.0-51249110220 10.1016/j.numecd.2007.09.001
37. Fasshauer M., Waldeyer T., Seeger J., Schrey S., Ebert T., Kratzsch J., Lossner U., Bluher M., Stumvoll M., Faber R., Stepan H., Serum levels of the adipokine visfatin are increased in pre-eclampsia. Clinical Endocrinology 2008 69 1 69 73 2-s2.0-45349099943 10.1111/j.1365-2265.2007.03147.x (Pubitemid 351847262)
38. Tan H., Zhong M., Gong H., Wang S., Zhang Y., Zhang W., Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clinical Endocrinology 2008 69 6 878 884 2-s2.0-49649128362 10.1111/j.1365-2265. 2008.03248.x
39. Pepene C. E., Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clinical Endocrinology 2012 76 1 119 125 2-s2.0-83455163980 10.1111/j.1365-2265.2011.04171.x
40. Liu S. W., Qiao S. B., Yuan J. S., Liu D. Q., Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clinical Endocrinology 2009 71 2 202 207 2-s2.0-67650327064 10.1111/j.1365-2265.2008.03453.x
41. Yilmaz M. I., Saglam M., Carrero J. J., Qureshi A. R., Caglar K., Eyileten T., Sonmez A., Cakir E., Yenicesu M., Lindholm B., Stenvinkel P., Axelsson J., Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrology Dialysis Transplantation 2008 23 3 959 965 2-s2.0-42449149616 10.1093/ndt/gfm727 (Pubitemid 351767576)
42. Axelsson J., Witasp A., Carrero J. J., Qureshi A. R., Suliman M. E., Heimbürger O., Bárány P., Lindholm B., Alvestrand A., Schalling M., Nordfors L., Stenvinkel P., Circulating levels of Visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. American Journal of Kidney Diseases 2007 49 2 237 244 2-s2.0-33846630857 10.1053/j.ajkd.2006.11.021 (Pubitemid 46178402)
43. Malyszko J., Malyszko J. S., Mysliwiec M., Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients. Transplantation Proceedings 2009 41 1 150 153 2-s2.0-60649114315 10.1016/j.transproceed.2008.10.086
44. Malyszko J., Malyszko J. S., Pawlak K., Mysliwiec M., Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Advances in Medical Sciences 2008 53 32 36 2-s2.0-55249089945 10.2478/v10039-008-0024-x
45. Kato A., Odamaki M., Ishida J., Hishida A., Relationship between serum Pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. American Journal of Nephrology 2008 29 1 31 35 2-s2.0-47949101183 10.1159/000148648
46. Yilmaz M. I., Saglam M., Carrero J. J., Qureshi A. R., Caglar K., Eyileten T., Sonmez A., Oguz Y., Aslan I., Vural A., Yenicesu M., Stenvinkel P., Lindholm B., Axelsson J., Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clinical Transplantation 2009 23 2 241 248 2-s2.0-64349119763 10.1111/j.1399-0012.2008.00921.x
47. Lu L. F., Yang S. S., Wang C. P., Hung W., Yu T., Chiu C., Chung F., Shin S., Lee Y., Elevated Visfatin/Pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke. Journal of Stroke and Cerebrovascular Diseases 2009 18 5 354 359 2-s2.0-69149100440 10.1016/j.jstrokecerebrovasdis.2009.01.003
48. Yu T. H., Lu L. F., Hung W. C., Chiu C., Liu Y., Yang C., Tsai I.-., Yen Y., Chen C., Wang C., Circulating visfatin level at admission is associated with occlusion of the infarct-related artery in patients with acute ST-segment elevation myocardial infarction. Acta Cardiologica Sinica 2011 27 2 77 85 2-s2.0-80052186956
49. Lu L. F., Wang C. P., Yu T. H., Hung W., Chiu C., Chung F., Tsai I., Yang C., Cheng Y., Lee Y., Yeh L., Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction. Cytokine 2012 57 1 74 80 2-s2.0-84155160623 10.1016/j.cyto.2011.10.015
50. Laudes M., Oberhauser F., Schulte D. M., Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Hormone and Metabolic Research 2010 42 4 268 273 10.1055/s-0029-1243638
51. Oki K., Yamane K., Kamei N., Nojima H., Kohno N., Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clinical Endocrinology 2007 67 5 796 800 2-s2.0-35448980420 10.1111/j.1365-2265.2007. 02966.x (Pubitemid 47628470)
52. Brancati F. L., Whelton P. K., Randall B. L., Neaton J. D., Stamler J., Klag M. J., Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Journal of the American Medical Association 1997 278 23 2069 2074 2-s2.0-0031445530 (Pubitemid 28016228)
53. Humphrey L. L., Ballard D. J., Frohnert P. P., Chu C.P., O'Fallon M., Palumbo P. J., Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. Annals of Internal Medicine 1989 111 10 788 796 2-s2.0-0024446017 (Pubitemid 19283914)
54. Kowalska I., Straczkowski M., Nikolajuk A., Adamska A., Karczewska-Kupczewska M., Otziomek E., Wolczynski S., Gorska M., Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Human Reproduction 2007 22 7 1824 1829 2-s2.0-34447336403 10.1093/humrep/dem118 (Pubitemid 47062747)
55. Steegers E. A., von Dadelszen P., Duvekot J. J., Pijnenborg R., Pre-eclampsia. The Lancet 2010 376 9741 631 644 2-s2.0-77956061313 10.1016/S0140-6736(10)60279-6
56. Ferreira A. F., Rezende J. C., de Cassia C. O. R., Maternal serum visfatin at 11-13 weeks' gestation in preeclampsia. Journal of Human Hypertension 2013 27 4 261 264 10.1038/jhh.2012.10
57. Zulfikaroglu E., Isman F., PayaslI A., KIlIc S., Kucur M., DanIsman N., Plasma visfatin levels in preeclamptic and normal pregnancies. Archives of Gynecology and Obstetrics 2010 281 6 995 998 2-s2.0-77953650085 10.1007/s00404-009-1192-z
58. Hu W., Wang Z., Wang H., Huang H., Dong M., Serum visfatin levels in late pregnancy and pre-eclampsia. Acta Obstetricia et Gynecologica Scandinavica 2008 87 4 413 418 2-s2.0-41649118423 10.1080/00016340801976012 (Pubitemid 351481708)
59. Kim S. C., Park M. J., Joo B. S., Decreased expressions of vascular endothelial growth factor and visfatin in the placental bed of pregnancies complicated by preeclampsia. Journal of Obstetrics and Gynaecology Research 2012 38 4 665 673 10.1111/j.1447-0756.2011.01773.x
60. Roberts J. M., Cooper D. W., Pathogenesis and genetics of pre-eclampsia. The Lancet 2001 357 9249 53 56 2-s2.0-0035814640 10.1016/S0140-6736(00)03577-7 (Pubitemid 32056505)
61. Ognjanovic S., Bryant-Greenwood G. D., Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. American Journal of Obstetrics and Gynecology 2002 187 4 1051 1058 2-s2.0-0036795752 10.1067/mob.2002.126295 (Pubitemid 35178410)
62. Filippatos T. D., Randeva H. S., Derdemezis C. S., Visfatin/PBEF and atherosclerosis-related diseases. Current Vascular Pharmacology 2010 8 1 12 28 10.2174/157016110790226679
63. Dahl T. B., Yndestad A., Skjelland M., Øie E., Dahl A., Michelsen A., Damås J. K., Tunheim S. H., Ueland T., Smith C., Bendz B., Tonstad S., Gullestad L., Frøland S. S., Krohg-Sørensen K., Russell D., Aukrust P., Halvorsen B., Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007 115 8 972 980 2-s2.0-33847279330 10.1161/CIRCULATIONAHA.106.665893 (Pubitemid 46328290)
64. Spiroglou S. G., Kostopoulos C. G., Varakis J. N., Papadaki H. H., Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. Journal of Atherosclerosis and Thrombosis 2010 17 2 115 130 2-s2.0-77649197301
65. Wang P., Vanhoutte P. M., Miao C. Y., Visfatin and cardio-cerebro- vascular disease. Journal of Cardiovascular Pharmacology 2011 59 1 1 9
66. Liu L. Y., Wang F., Zhang X. Y., Nicotinamide phosphoribosyltransferase may be involved in age-related brain diseases. PLoS One 2012 7 10 e44933
67. Brentano F., Schorr O., Ospelt C., Stanczyk J., Gay R. E., Gay S., Kyburz D., Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis and Rheumatism 2007 56 9 2829 2839 2-s2.0-34848847894 10.1002/art.22833 (Pubitemid 47502729)
68. Nowell M. A., Richards P. J., Fielding C. A., Ognjanovic S., Topley N., Williams A. S., Bryant-Greenwood G., Jones S. A., Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis and Rheumatism 2006 54 7 2084 2095 2-s2.0-33745894354 10.1002/art.21942 (Pubitemid 44051064)
69. Moschen A. R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., Tilg H., Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. Journal of Immunology 2007 178 3 1748 1758 2-s2.0-33846527541 (Pubitemid 46154646)
70. Ye S. Q., Simon B. A., Maloney J. P., Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. American Journal of Respiratory and Critical Care Medicine 2005 171 4 361 370 10.1164/rccm.200404- 563OC (Pubitemid 40223404)
71. Jia S. H., Li Y., Parodo J., Kapus A., Fan L., Holstein O. D., Marshall J. C., Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. Journal of Clinical Investigation 2004 113 9 1318 1327 2-s2.0-2342650912 10.1172/JCI200419930 (Pubitemid 39069931)
72. Ognjanovic S., Bao S., Yamamoto S. Y., Garibay-Tupas J., Samal B., Bryant-Greenwood G. D., Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. Journal of Molecular Endocrinology 2001 26 2 107 117 2-s2.0-0035062540 10.1677/jme.0.0260107 (Pubitemid 32266186)
73. Mesko B., Poliska S., Szegedi A., Szekanecz Z., Palatka K., Papp M., Nagy L., Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. BMC Medical Genomics 2010 3 15 2-s2.0-77951803595 10.1186/1755-8794-3-15
74. Senolt L., Krystufkova O., Hulejova H., Kuklová M., Filková M., Cerezo L. A., Haluzík M., Gay S., Pavelka K., Vencovský J., The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. Cytokine 2011 55 1 116 121 2-s2.0-79956360551 10.1016/j.cyto.2011.04. 004
75. Gerdes S., Osadtschy S., Rostami-Yazdi M., Leptin, adiponectin, visfatin and retinol-binding protein-4-mediators of comorbidities in patients with psoriasis? Experimental Dermatology 2012 21 1 43 47 10.1111/j.1600-0625.2011. 01402.x
76. Scotece M., Conde J., Gomez R., Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases. Mediators of Inflammation 2012 2012 125458 10.1155/2012/125458
77. Moulton K. S., Angiogenesis in atherosclerosis: gathering evidence beyond speculation. Current Opinion in Lipidology 2006 17 5 548 555 10.1097/01.mol.0000245261.71129.f0 (Pubitemid 44372686)
78. Adya R., Tan B. K., Punn A., Chen J., Randeva H. S., Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovascular Research 2008 78 2 356 365 2-s2.0-42349084337 10.1093/cvr/cvm111 (Pubitemid 351556097)
79. Kim S. R., Bae S. K., Choi K. S., Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochemical and Biophysical Research Communications 2007 357 1 150 156 10.1016/j.bbrc.2007.03. 105 (Pubitemid 46574511)
80. Lovren F., Pan Y., Shukla P. C., Quan A., Teoh H., Szmitko P. E., Peterson M. D., Gupta M., Al-Omran M., Verma S., Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. American Journal of Physiology 2009 296 6 E1440 E1449 2-s2.0-66849111706 10.1152/ajpendo.90780.2008
81. Xiao J., Xiao Z., Liu Z., Gong H., Yuan Q., Wang S., Li Y., Jiang D., Involvement of dimethylarginine dimethylaminohydrolase-2 in visfatin-enhanced angiogenic function of endothelial cells. Diabetes/Metabolism Research and Reviews 2009 25 3 242 249 2-s2.0-65649123838 10.1002/dmrr.939
82. Adya R., Tan B. K., Chen J., Randeva H. S., Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis 2009 205 1 113 119 2-s2.0-67349083892 10.1016/j.atherosclerosis.2008.11.024
83. Bae Y., Bae M., Kim S., Lee J. H., Wee H., Bae S., Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis. Biochemical and Biophysical Research Communications 2009 379 2 206 211 2-s2.0-58149499166 10.1016/j.bbrc.2008.12.042
84. Lee W. J., Wu C. S., Lin H., Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. International Journal of Obesity 2009 33 4 465 472 10.1038/ijo.2009.24
85. Kim S. R., Jung Y. H., Park H. J., Upregulation of thromboxane synthase mediates visfatin-induced interleukin-8 expression and angiogenic activity in endothelial cells. Biochemical and Biophysical Research Communications 2012 418 4 662 668 10.1016/j.bbrc.2012.01.072
86. Zhang W., Xie Y., Wang T., Bi J., Li H., Zhang L. Q., Ye S. Q., Ding S., Neuronal protective role of PBEF in a mouse model of cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism 2010 30 12 1962 1971 2-s2.0-78649696643 10.1038/jcbfm.2010.71
87. Tian W., Zhu Y., Wang Y., Visfatin, a potential biomarker and prognostic factor for endometrial cancer. Gynecologic Oncology 2013 129 3 505 512 10.1016/j.ygyno.2013.02.022
88. Fazeli M. S., Dashti H., Akbarzadeh S., Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine 2013 62 1 81 85 10.1016/j.cyto.2013.02.012
89. Nakajima T. E., Yamada Y., Hamano T., Furuta K., Gotoda T., Katai H., Kato K., Hamaguchi T., Shimada Y., Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. Journal of Gastroenterology 2009 44 7 685 690 2-s2.0-68149092537 10.1007/s00535-009-0063-5
90. Montecucco F., Cea M., Bauer I., Nicotinamide phosphoribosyltransferase (Nampt) inhibitors as therapeutics: rationales, controversies, clinical experience. Current Drug Targets 2013 14 6 637 643
91. Pogrebniak A., Schemainda I., Azzam K., Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. European Journal of Medical Research 2006 11 8 313 321 (Pubitemid 44390171)
92. Ravaud A., Cerny T., Terret C., Wanders J., Bui B. N., Hess D., Droz J., Fumoleau P., Twelves C., Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. European Journal of Cancer 2005 41 5 702 707 2-s2.0-14844291424 10.1016/j.ejca.2004.12.023 (Pubitemid 40342552)
93. Yu X. Y., Qiao S. B., Guan H. S., Effects of visfatin on proliferation and collagen synthesis in rat cardiac fibroblasts. Hormone and Metabolic Research 2010 42 7 507 513 10.1055/s-0030-1249059
94. Pillai V. B., Sundaresan N. R., Kim G., Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling. American Journal of Physiology 2013 304 3 415 426 10.1152/ajpheart.00468.2012
95. Li Y., Zhang Y., Dorweiler B., Cui D., Wang T., Woo C. W., Brunkan C. S., Wolberger C., Imai S., Tabas I., Extracellular nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. Journal of Biological Chemistry 2008 283 50 34833 34843 2-s2.0-58049200121 10.1074/jbc.M805866200
96. Romacho T., Azcutia V., Vázquez-Bella M., Matesanz N., Cercas E., Nevado J., Carraro R., Rodríguez-Mañas L., Sánchez-Ferrer C. F., Peiró C., Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 2009 52 11 2455 2463 2-s2.0-70349849659 10.1007/s00125-009-1509-2
97. Kim S. R., Bae Y. H., Bae S. K., Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochimica et Biophysica Acta 2008 1783 5 886 895 10.1016/j.bbamcr.2008.01.004
98. Liu S. W., Qiao S. B., Yuan J. S., Liu D. Q., Visfatin stimulates production of monocyte chemotactic protein-1 and interleukin-6 in human vein umbilical endothelial cells. Hormone and Metabolic Research 2009 41 4 281 286 2-s2.0-65649107670 10.1055/s-0028-1102914
99. Adya R., Tan B. K., Chen J., Randeva H. S., Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells. Diabetes Care 2008 31 4 758 760 2-s2.0-48649109765 10.2337/dc07-1544
100. Vallejo S., Romacho T., Angulo J., Villalobos L. A., Cercas E., Leivas A., Bermejo E., Carraro R., Sánchez-Ferrer C. F., Peiró C., Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity. PLoS One 2011 6 11 2-s2.0-80455132084 10.1371/journal.pone.0027299 e27299
101. Boini K. M., Zhang C., Xia M., Han W., Brimson C., Poklis J. L., Li P., Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells. Biochimica et Biophysica Acta 2010 1801 12 1294 1304 2-s2.0-77957970685 10.1016/j.bbalip.2010.09.001
102. Xia M., Zhang C., Boini K. M., Thacker A. M., Li P., Membrane raftlysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin. Cardiovascular Research 2011 89 2 401 409 2-s2.0-78751475177 10.1093/cvr/cvq286
103. Zhou F., Pan Y., Huang Z., Visfatin induces cholesterol accumulation in macrophages through up-regulation of scavenger receptor-A and CD36. Cell Stress and Chaperones 2013 10.1007/s12192-013-0417-z
104. Pacher P., Obrosova I. G., Mabley J. G., Szabó C., Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Current Medicinal Chemistry 2005 12 3 267 275 2-s2.0-14544297961 (Pubitemid 40305619)
105. Galkina E., Ley K., Vascular adhesion molecules in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 2292 2301 10.1161/ATVBAHA.107.149179 (Pubitemid 350203942)
106. Touyz R. M., Briones A. M., Reactive oxygen species and vascular biology: implications in human hypertension. Hypertension Research 2011 34 1 5 14 2-s2.0-78650882643 10.1038/hr.2010.201
107. Xia M., Zhang C., Boini K. M., Thacker A. M., Li P., Membrane raftlysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin. Cardiovascular Research 2011 89 2 401 409 2-s2.0-78751475177 10.1093/cvr/cvq286
108. Huang Q., Guo Y., Zeng H., Xie W., Yan H., Ding H., Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Endocrine Research 2011 36 3 93 100 2-s2.0-79960115423 10.3109/07435800.2010.539992
109. Chiu C. A., Yu T. H., Hung W. C., Increased expression of visfatin in monocytes and macrophages in male acute myocardial infarction patients. Mediators of Inflammation 2012 2012 7 469852 10.1155/2012/469852
110. Oviedo-Orta E., Bermudez-Fajardo A., Karanam S., Benbow U., Newby A. C., Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology 2008 124 1 42 50 2-s2.0-42149117908 10.1111/j.1365-2567.2007.02728.x (Pubitemid 351537571)
111. Song H. K., Lee M. H., Kim B. K., Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. American Journal of Physiology 2008 295 5 1485 1494
112. Hausenloy D. J., Yellon D. M., The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. Journal of Molecular and Cellular Cardiology 2003 35 4 339 341 2-s2.0-0037383432 10.1016/S0022-2828(03)00043-9 (Pubitemid 36411694)
113. Hsu C. P., Oka S., Shao D., Hariharan N., Sadoshima J., Nicotinamide phosphoribosyltransferase regulates cell survival through nad+ synthesis in cardiac myocytes. Circulation Research 2009 105 5 481 491 2-s2.0-70149095672 10.1161/CIRCRESAHA.109.203703
114. Lim S. Y., Davidson S. M., Paramanathan A. J., Smith C. C. T., Yellon D. M., Hausenloy D. J., The novel adipocytokine visfatin exerts direct cardioprotective effects. Journal of Cellular and Molecular Medicine 2008 12 4 1395 1403 2-s2.0-49549089810 10.1111/j.1582-4934.2008.00332.x
115. Wang P., Xu T., Guan Y., Tian W., Viollet B., Rui Y., Zhai Q., Su D., Miao C., Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Annals of Neurology 2011 69 2 360 374 2-s2.0-79952537492 10.1002/ana.22236
116. Rask-Madsen C., King G. L., Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nature Clinical Practice Endocrinology & Metabolism 2007 3 1 46 56 10.1038/ncpendmet0366 (Pubitemid 46006612)
117. Yamawaki H., Hara N., Okada M., Hara Y., Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochemical and Biophysical Research Communications 2009 383 4 503 508 2-s2.0-65449181941 10.1016/j.bbrc.2009.04.074
118. Song H. K., Lee M. H., Kim B. K., Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. American Journal of Physiology 2008 295 5 1485 1494 10.1152/ajprenal.90231.2008
119. Busso N., Karababa M., Nobile M., Rolaz A., Van Gool F., Galli M., Leo O., So A., De Smedt T., Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 2008 3 5 2-s2.0-48249105497 10.1371/journal.pone.0002267 e2267
120. Montecucco F., Bauer I., Braunersreuther V., Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxidants & Redox Signaling 2013 18 6 630 641
121. Jacques C., Holzenberger M., Mladenovic Z., Proinflammatory actions of visfatin/nicotinamide phosphoribosyltransferase (Nampt) involve regulation of insulin signaling pathway and Nampt enzymatic activity. Journal of Biological Chemistry 2012 287 18 15100 15108 10.1074/jbc.M112.350215
122. Touyz R. M., Lipid rafts take center stage in endothelial cell redox signaling by death receptors. Hypertension 2006 47 1 16 18 2-s2.0-31744449420 10.1161/01.HYP.0000196730.13216.f3 (Pubitemid 43177808)
123. 2 -induced myocardial apoptosis: a missing link between obesity and cardiovascular disease. Journal of Cellular Physiology 2012 228 3 495 501
124. Iacobellis G., Assael F., Ribaudo M. C., Zappaterreno A., Alessi G., Di Mario U., Leonetti F., Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obesity Research 2003 11 2 304 310 2-s2.0-0042229359 (Pubitemid 41127400)
125. Iacobellis G., Ribaudo M. C., Assael F., Vecci E., Tiberti C., Zappaterreno A., Di Mario U., Leonetti F., Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. Journal of Clinical Endocrinology and Metabolism 2003 88 11 5163 5168 2-s2.0-0344442670 10.1210/jc.2003-030698 (Pubitemid 37452712)
126. Williams M. R., Kataoka N., Sakurai Y., Powers C. M., Eskin S. G., McIntire L. V., Gene expression of endothelial cells due to interleukin-1 beta stimulation and neutrophil transmigration. Endothelium 2008 15 1-2 73 84 2-s2.0-46049101617 10.1080/10623320802092443 (Pubitemid 351894981)